News

The immuno-oncology combination Opdivo (10mg/mL) and Yervoy (5mg/mL) has been indicated to be intravenously injected in patients with intermediate or poor-risk, advanced RCC, who were previously untreated for

Under the deal, Servier will acquire oncology treatment Oncaspar (pegaspargase), as well as ex-US rights of Onivyde (irinotecan pegylated liposomal formulation). Oncaspar is a component of multi-agent treatment

The company has determined that additional investments of time and resources in these programs are not appropriate given the other opportunities in its product development pipeline. The terminated

Study results showed KEYTRUDA significantly prolonged recurrence-free survival (RFS), reducing the risk of disease recurrence or death by 43% compared to placebo in the overall study population (HR=0.57

The findings come from a phase 3 trial called FLAURA which assessed the efficacy and safety of Tagrisso 80mg, administered orally daily at 80mg in comparison with 150mg

The investment bolsters the company’s Canadian operations and its commitment to advancing public health around the world. The announcement will be made during an event today at Sanofi

CEPI will fund up to $56m to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine.  The shared

Under the agreement, GSK will receive a 19.9% stake in Orchard and get a seat on its board.  The acquisition of the portfolio, which includes both approved and investigational therapies

The personalized vaccine is made from patients’ own immune cells, which are exposed in the laboratory to the contents of the patients’ tumor cells, and then injected into